Pulse Biosciences (NSDQ:PLSE) announced today that it appointed Mitchell E. Levinson to its newly created chief strategy officer role.
Hayward, Calif.-based Pulse Biosciences said in a news release that Levinson’s new role, which begins effective immediately, will be held in addition to his position as a member of the company’s board of directors.
Pulse Biosciences develops the CellFX system, powered by nano-pulse stimulation, for the delivery of nanosecond pulses of electrical energy designed to clear cells while sparing adjacent non-cellular tissue.
“As a board member and medical device industry veteran with a track record of successfully bringing new technologies and products to market across a variety of medical specialties, Mitch’s insights have benefitted Pulse Biosciences for over five years,” Pulse Biosciences president & CEO Darrin Uecker said in the release. “We are thrilled to add him to the executive leadership team at this critical time as we continue to build our dermatology business and accelerate our expansion into a multi-specialty company by leveraging our existing CellFX platform with CellFX CloudConnect. We believe Mitch is uniquely qualified to spearhead our expansion efforts with his broad experience and skillset.”
Levinson, a veteran of more than 30 years in the medical device space, most recently co-founded and served as CEO for startup Cerebrotech Medical Systems. He was the first employee and startup CEO for Zeltiq Aesthetics, which Allergan acquired in 2017.
“As one of Pulse Biosciences’ early board members, I have had the privilege of working closely with the board and management team over the years to develop the company’s strategy and vision for our highly differentiated and proprietary NPS technology,” Levinson said. “I am very excited to be joining the executive team at this important time in the company’s growth as we pursue the use of our NPS technology beyond dermatology, where I am confident we can offer additional safe and effective medical interventions to improve patient care and address unmet needs for healthcare providers.”
